OKAY
833230
CHANGFU CO.,LTD
871396
Gansu Longshenrongfa Pharmaceutical Industry
300534
4
Tibet Duo Rui Pharmaceutical
301075
5
Chengda Pharmaceuticals
301201
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 29, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 29, 2023 | (Q2)Jul 2, 2023 | (Q1)Apr 2, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | 19.59%24.38M | -40.80%3.13M | 156.54%6.53M | -14.80%7.34M | 87.38%7.38M | 717.76%20.39M | 134.47%5.29M | 137.57%2.55M | 278.13%8.61M | 3.94M |
Net income from continuing operations | 67.35%-3.34M | -198.20%-981K | -130.45%-804K | -129.22%-761K | 95.19%-792K | -142.37%-10.22M | -42.32%999K | -43.26%2.64M | -18.01%2.6M | ---16.47M |
Operating gains losses | -17.65%14K | --2K | --3K | --1K | --8K | 183.33%17K | ---- | ---- | ---- | ---- |
Depreciation and amortization | -0.06%7.77M | -7.68%1.89M | -6.89%1.89M | 2.17%1.98M | 14.23%2.01M | 91.76%7.77M | 87.96%2.05M | 77.55%2.03M | 110.30%1.94M | --1.76M |
Deferred tax | 76.65%-1.19M | -5,211.76%-869K | -196.92%-189K | --0 | 97.55%-127K | -315.68%-5.08M | -98.51%17K | --195K | -146.31%-94K | ---5.19M |
Other non cash items | -204.69%-983K | -434.05%-1.09M | -66.46%107K | -102.21%-5K | -94.12%4K | 105.40%939K | 187.87%326K | 739.47%319K | 545.71%226K | --68K |
Change In working capital | 637.68%19.05M | 129.37%3.59M | 237.23%4.65M | 49.06%5.39M | 587.94%5.42M | 114.45%2.58M | 194.56%1.56M | 74.15%-3.39M | 251.63%3.62M | --788K |
-Change in receivables | 19.35%14.52M | -47.12%5.48M | 96.65%-197K | 37.22%5.5M | 1.83%3.73M | 182.22%12.16M | 526.84%10.37M | 58.95%-5.88M | 673.10%4.01M | --3.67M |
-Change in prepaid assets | 361.78%5.87M | 288.30%4.65M | 55.89%516K | -152.05%-355K | 234.57%1.06M | -451.96%-2.24M | -106.26%-2.47M | -9.32%331K | -59.62%682K | ---784K |
-Change in payables and accrued expense | 72.51%-2.13M | 19.57%-2.56M | -58.70%710K | 94.76%-164K | 96.42%-113K | -591.94%-7.75M | -485.49%-3.19M | 59.91%1.72M | -1,267.25%-3.13M | ---3.15M |
-Change in other current assets | -0.56%716K | -56.20%-4.69M | 337.82%3.45M | -16.26%1.26M | -51.44%693K | 9.09%720K | -945.63%-3M | 688.00%788K | 538.56%1.51M | --1.43M |
-Change in other current liabilities | --0 | --0 | ---- | ---- | ---- | 78.33%-1M | --0 | ---- | ---- | ---- |
-Change in other working capital | -88.90%77K | 587.50%702K | -74.08%169K | -252.89%-847K | 114.40%53K | 152.22%694K | 86.74%-144K | 1,186.67%652K | 111.95%554K | ---368K |
Cash from discontinued investing activities | 0 | 0 | ||||||||
Operating cash flow | 19.59%24.38M | -40.80%3.13M | 156.54%6.53M | -14.80%7.34M | 87.38%7.38M | 386.24%20.39M | 646.40%5.29M | 137.57%2.55M | 1,381.25%8.61M | --3.94M |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | 82.76%-1.64M | 64.24%-270K | 29.11%-375K | 93.31%-501K | 33.69%-494K | -6.92%-9.51M | 97.81%-755K | 53.68%-529K | -403.36%-7.49M | -745K |
Capital expenditure reported | 36.85%-1.64M | 53.29%-270K | 29.11%-375K | 32.75%-501K | 33.69%-494K | 54.28%-2.6M | 42.20%-578K | 54.00%-529K | 49.63%-745K | ---745K |
Net business purchase and sale | --0 | --0 | --0 | ---- | ---- | -114.95%-6.92M | 99.47%-177K | --0 | ---- | ---- |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | 82.76%-1.64M | 64.24%-270K | 29.11%-375K | 93.31%-501K | 33.69%-494K | -6.61%-9.51M | 97.81%-755K | 53.68%-529K | -403.36%-7.49M | ---745K |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | -105.91%-22.39M | 38.90%-2.77M | -128.62%-6.12M | -1,144.67%-6.66M | -118.85%-6.84M | -168.23%-10.87M | -113.41%-4.54M | -133.99%-2.68M | -124.29%-535K | -3.12M |
Net issuance payments of debt | -331.91%-15.93M | 27.91%-2.14M | -84.26%-2.13M | -425.53%-6.78M | -196.11%-4.87M | -116.09%-3.69M | -108.37%-2.97M | -112.33%-1.16M | -40.96%2.08M | ---1.65M |
Net common stock issuance | --262K | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
Cash dividends paid | 74.81%-1.64M | --0 | --0 | --0 | -1.30%-1.64M | -3.45%-6.51M | -3.49%-1.63M | -3.49%-1.63M | -3.44%-1.63M | ---1.62M |
Proceeds from stock option exercised by employees | -10.35%459K | -295.06%-158K | 148.62%271K | -25.42%132K | 47.59%214K | -21.59%512K | -30.77%81K | -6.84%109K | -29.20%177K | --145K |
Net other financing activities | -365.85%-5.54M | -4,800.00%-735K | -426,000.00%-4.26M | 99.40%-7K | -10,660.00%-538K | 11.73%-1.19M | 91.85%-15K | 101.89%1K | ---1.17M | ---5K |
Cash from discontinued financing activities | ||||||||||
Financing cash flow | -105.91%-22.39M | 38.90%-2.77M | -128.62%-6.12M | -1,144.67%-6.66M | -118.85%-6.84M | -168.23%-10.87M | -113.41%-4.54M | -133.99%-2.68M | -124.29%-535K | ---3.12M |
Net cash flow | ||||||||||
Beginning cash position | --0 | --262K | -65.76%226K | -28.57%50K | --0 | --0 | --0 | 1,366.67%660K | --70K | --0 |
Current changes in cash | --353K | --91K | --36K | -70.17%176K | -28.57%50K | ---- | ---- | ---- | 1,211.11%590K | --70K |
End cash Position | --353K | --353K | --262K | -65.76%226K | -28.57%50K | --0 | --0 | --0 | 1,366.67%660K | --70K |
Free cash flow | 27.83%22.74M | -39.27%2.86M | 205.26%6.15M | -13.10%6.84M | 115.62%6.89M | 238.95%17.79M | 1,719.93%4.71M | 125.44%2.02M | 465.64%7.87M | --3.19M |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |